astellas-white-logo

This website is intended for Healthcare Professionals in India only.

Menu
Padcev Logo

PADCEVTM is an ADC targeted against Nectin-41

Nonclinical data suggest that the anticancer activity of PADCEV is a result of the following1:

padcev microtubule
padcev adcnectin4
human kappa

With no biomarker testing required, PADCEV can be initiated at the first sign of progression following platinum-based chemotherapy and a PD-1/PD-L1 inhibitor1,2

1L - first-line; 2L - second-line; ADC - antibody-drug conjugate; IgG1 - immunoglobulin G1; mAB - monoclonal antibody; MMAE - monomethyl auristatin E; MoA - mechanism of action; PD-1 - programmed death receptor-1; PD-L1 - programmed death-ligand 1

References

  1. PADCEV India prescribing information.
  2. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125-35.

Efficacy outcomes

Review efficacy outcomes in 2L+ locally advanced or metastatic UC

Safety outcomes


See safety results for 2L+ locally advanced or metastatic UC

Resources and treatment support

Access resources to help navigate treatment with confidence

PADCEV, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. 

 

PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.

Adverse Event Reporting

Adverse Events (AE) should be reported. Kindly report an adverse event/side effect related to an Astellas product on
pv@in.astellas.com or +91-226-1557-616

Have a Medical Information Question?

Medical Enquiries:

To submit a question about Astellas products, please contact us:

medinfo.id@astellas.com